As 2008 draws to a close, Express Pharma decided to recap important milestones of this year, which we featured through our Cover Stories and other columns. All in all, a smorgasbord of views, reflecting the times and travails of the Indian pharma industry in 2008.

As 2008 draws to a close, Express Pharma decided to recap important milestones of this year, which we featured through our Cover Stories and other columns. All in all, a smorgasbord of views, reflecting the times and travails of the Indian pharma industry in 2008.

NPIL is now Piramal Healthcare
After 20 years of operations, Nicholas Piramal India Limited (NPIL) is acquiring a new corporate identity—Piramal Healthcare

Taro calls off merger with Sun Pharma
Israel’s Taro Pharmaceuticals recently terminated its merger agreement with Sun Pharma

Ranbaxy wins UK SFO case
Ranbaxy Laboratories announced that the UK Serious Fraud Office’s (SFO) prosecution of its UK subsidiary, Ranbaxy UK Ltd (RUKL), has been quashed by the English Crown Court

Sun Pharma wins case against Taro
Sun Pharmaceutical won a case in Israel which was filed against by Taro regarding an open offer for the latter

Ranbaxy becomes Daiichi Sankyo subsidiary
Ranbaxy Laboratories and Daiichi Sankyo announced that the Committee of the Board of Directors of Ranbaxy approved the allotment of equity shares and warrants on a preferential basis to Daiichi Sankyo

Racing to the top
With the surge of clinical research (CR) in India, the dearth of adequately trained professionals could seriously hinder the reputation and growth of the CR industry in India. The fact of the matter is that India cannot afford to be left behind and let the CR opportunity pass on to other countries. Aashruti Kak finds out what is not going right… (Extracted from Express Pharma, 16-31 January 2008)

Opting for the co-opetitive approach
The risky business of drug discovery has resulted in a new ‘co-opetitive’ approach. Today, many Indian pharma companies are partnering with Big Pharma, giving rise to different collaborative drug discovery models. Arshiya Khan reveals… (Extracted from Express Pharma, 1-15 April 2008)

Playing on the same team
Amidst growing concern about a financial crunch and heavy pressure to develop new molecules, the concept of public private partnerships (PPPs) has evolved as an able rescuer to drug developers. Sachin Jagdale reports… (Extracted from Express Pharma, 16-30 June 2008)

The chase begins
Strategic move or sell out, the Ranbaxy Laboratories-Daiichi Sankyo deal could mark the beginning of a new era in the Indian pharmaceutical market. As players realign themselves to their new role as prey rather than predators, Arshiya Khan and Suja Nair analyse different options… (Extracted from Express Pharma, 1-15 July 2008)

Cementing the gap
While trade associations act as a catalyst in boosting the growth of the Indian pharma industry, they are also trying hard to bridge the gap between the industry and the Government. Arshiya Khan analyses the role of these associations… (Extracted from Express Pharma, 1-15 August 2008)

Pharma’s new prescription—hospitals?
Is the slow down in the global pharma industry forcing Indian companies to look more closely at hospitals? That’s reason enough for leaders of both industries to share space on the same page. Arshiya Khan finds out more… (Extracted from Express Pharma, 16-31 August 2008)

Reducing patient dropouts
Is India’s patient pool showing the first signs of drying up? Or is it a case of a lack of investigators to get to the right patients? Usha Sharma analyses… (Extracted from Express Pharma, 1-15 September 2008)

Behind the smokescreen
As anti-smoking campaigns become more visible, the market for nicotine replacement therapies will also pick up. Suja Nair explores… (Extracted from Express Pharma, 16-30 September 2008)

Are emergency contraceptive pills a necessary evil?
Increased use of emergency contraceptive pills has become the talk of the town. But is it really safe to pop in one like a routine pill? Suja Nair explores… (Extracted from Express Pharma, 16-31 April 2008)